UK sets up vaccines centre as Brexit looms; Shanghai's Elpiscience bags $35M in Series B
→ Hillhouse Capital has joined Lilly Asia Ventures and CDH Investments in backing Elpiscience, leading a $35 million Series B to boost its cancer immunotherapy pipeline. The Shanghai-based biotech is gearing up IND filing for two of its 12 assets, several of which are in-licensed from regional and global institutions.
→ With Brexit threatening to disrupt the pharmaceutical supply chain in the country, and having lost the EMA headquarters to Amsterdam, the UK is working on ways to salvage its £70 billion life sciences industry. Over the weekend, the government announced the first-ever vaccines manufacturing innovation centre to tackle deadly diseases such as Ebola and Lassa fever.